Page last updated: 2024-12-09

1-(2-chlorophenyl)-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(2-chlorophenyl)-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)thiourea, also known as **[5-(2-Chlorophenyl)-1,3-thiazol-2-yl]-(2-oxo-1,3-dihydro-1H-benzimidazol-5-yl)-amine**, is a synthetic molecule that possesses a unique structure with potential pharmacological activity.

**Here's a breakdown of its importance in research:**

* **Structure:** The molecule consists of a thiourea core, linked to a 2-chlorophenyl substituent and a 2-oxo-1,3-dihydrobenzimidazol-5-yl group. This combination of structural features is interesting for its potential to interact with various biological targets.

* **Potential Biological Activity:**
* **Antimicrobial Activity:** Thiourea derivatives are known to exhibit antimicrobial activity against a range of bacteria and fungi. This compound's structure, particularly the thiourea core, could contribute to its potential in inhibiting bacterial growth or disrupting fungal cell walls.
* **Anti-inflammatory Activity:** The benzimidazole moiety is often associated with anti-inflammatory properties. This component of the molecule might contribute to the compound's potential to suppress inflammation in various biological systems.
* **Anticancer Activity:** Some thiourea-containing compounds have been investigated for their anticancer potential. The specific structure of this molecule could make it suitable for interacting with cancer cells or inhibiting their growth.
* **Other Potential Activities:** The combination of the thiourea, chlorophenyl, and benzimidazole moieties might lead to other biological activities, such as anti-viral, anti-parasitic, or antioxidant properties.

* **Research Significance:** The unique structure of this compound makes it a valuable target for research in various fields:
* **Medicinal Chemistry:** This molecule can serve as a starting point for designing new drugs with improved efficacy and reduced side effects.
* **Pharmacology:** Studying this compound's biological activity can shed light on its potential therapeutic applications and its interactions with biological systems.
* **Drug Discovery:** Researchers can use this molecule as a lead compound for developing new pharmaceuticals, particularly in the areas of antimicrobial, anti-inflammatory, and anticancer drugs.

**It's important to note that:**

* This compound is still under investigation, and its exact mechanisms of action and potential applications are yet to be fully understood.
* Extensive research is needed to confirm its safety and efficacy before it can be considered for use in human medicine.

**In conclusion, 1-(2-chlorophenyl)-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)thiourea is a promising candidate for research in the field of medicinal chemistry and drug discovery, particularly in the areas of antimicrobial, anti-inflammatory, and anticancer drug development. However, further investigations are required to confirm its potential therapeutic applications.**

Cross-References

ID SourceID
PubMed CID2564703
CHEMBL ID1549091
CHEBI ID114390

Synonyms (14)

Synonym
OPREA1_283032
smr000154815
MLS000568920 ,
CHEBI:114390
1-(2-chlorophenyl)-3-(2-oxo-1,3-dihydrobenzimidazol-5-yl)thiourea
HMS2295D14
cid_2564703
1-(2-chlorophenyl)-3-(2-keto-1,3-dihydrobenzimidazol-5-yl)thiourea
1-(2-chlorophenyl)-3-(2-oxidanylidene-1,3-dihydrobenzimidazol-5-yl)thiourea
bdbm87765
CHEMBL1549091
Q27195791
Z45764695
AKOS034376236
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.28180.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency35.39730.140911.194039.8107AID2451
glp-1 receptor, partialHomo sapiens (human)Potency8.91250.01846.806014.1254AID624417
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency6.30960.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency22.38720.001815.663839.8107AID894
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
polyadenylate-binding protein 1Homo sapiens (human)IC50 (µMol)66.00004.910023.702976.1900AID602259; AID602260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]